Adenosine arrests breast cancer cell motility by A3 receptor stimulation

[1]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  M. Aubry,et al.  MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma , 2016, Oncotarget.

[3]  R. Broaddus,et al.  Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. , 2015, The Journal of clinical investigation.

[4]  W. Junger,et al.  Novel method for real‐time monitoring of ATP release reveals multiple phases of autocrine purinergic signalling during immune cell activation , 2015, Acta physiologica.

[5]  G. Dubini,et al.  Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation , 2014, Proceedings of the National Academy of Sciences.

[6]  S. Jalkanen,et al.  Adenosine Inhibits Tumor Cell Invasion via Receptor-Independent Mechanisms , 2014, Molecular Cancer Research.

[7]  Luzhe Sun,et al.  Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis , 2014, Oncogene.

[8]  L. Antonioli,et al.  Immunity, inflammation and cancer: a leading role for adenosine , 2013, Nature Reviews Cancer.

[9]  W. Junger,et al.  Pannexin 1 Channels Link Chemoattractant Receptor Signaling to Local Excitation and Global Inhibition Responses at the Front and Back of Polarized Neutrophils* , 2013, The Journal of Biological Chemistry.

[10]  P. Fishman,et al.  CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. , 2012, The oncologist.

[11]  N. Sträter,et al.  Cellular function and molecular structure of ecto-nucleotidases , 2012, Purinergic Signalling.

[12]  R. Merrill,et al.  Risk-adjusted female breast cancer incidence rates in the United States. , 2012, Cancer epidemiology.

[13]  M. Forghani,et al.  Expression of A1 and A3 Adenosine Receptors in Human Breast Tumors , 2012, Tumori.

[14]  Geoffrey Burnstock,et al.  Purinergic signalling , 2012, Acta physiologica.

[15]  E. Bulger,et al.  Increased Neutrophil Adenosine A3 Receptor Expression Is Associated With Hemorrhagic Shock and Injury Severity in Trauma Patients , 2011, Shock.

[16]  A. IJzerman,et al.  Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl)adenosine , 2011, Purinergic Signalling.

[17]  M. Smyth,et al.  CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. , 2011, Cancer research.

[18]  W. Junger,et al.  Immune cell regulation by autocrine purinergic signalling , 2011, Nature Reviews Immunology.

[19]  S. Fuqua,et al.  Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. , 2011, Cancer research.

[20]  F. Di Virgilio,et al.  The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation , 2010, Allergy.

[21]  M. Smyth,et al.  Extracellular adenosine triphosphate and adenosine in cancer , 2010, Oncogene.

[22]  A. Schwab,et al.  Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis , 2010, Science Signaling.

[23]  W. Junger,et al.  Purinergic Signaling: A Fundamental Mechanism in Neutrophil Activation , 2010, Science Signaling.

[24]  F. Fernández‐Avilés,et al.  Mechanisms by Which Adenosine Restores Conduction in Dormant Canine Pulmonary Veins , 2010, Circulation.

[25]  M. Barrachina,et al.  DNA methylation regulates adenosine A2A receptor cell surface expression levels , 2010, Journal of neurochemistry.

[26]  M. Smyth,et al.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis , 2010, Proceedings of the National Academy of Sciences.

[27]  Michael R. Elliott,et al.  Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance , 2009, Nature.

[28]  K. Watabe,et al.  Adenosine A3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity , 2009, Neoplasia.

[29]  P. Insel,et al.  Ecto-nucleoside Triphosphate Diphosphohydrolase 1 (E-NTPDase1/CD39) Regulates Neutrophil Chemotaxis by Hydrolyzing Released ATP to Adenosine* , 2008, Journal of Biological Chemistry.

[30]  A. Ohta,et al.  Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia , 2008, Clinical Cancer Research.

[31]  W. Junger,et al.  Hypertonic saline up-regulates A3 adenosine receptor expression of activated neutrophils and increases acute lung injury after sepsis* , 2008, Critical care medicine.

[32]  A. Zlotnik.  New insights on the role of CXCR4 in cancer metastasis , 2008, The Journal of pathology.

[33]  W. Junger.  Purinergic regulation of neutrophil chemotaxis , 2008, Cellular and Molecular Life Sciences.

[34]  Z. Ou,et al.  Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells , 2008, Journal of Cancer Research and Clinical Oncology.

[35]  W. Junger,et al.  A3 AND P2Y2 RECEPTORS CONTROL THE RECRUITMENT OF NEUTROPHILS TO THE LUNGS IN A MOUSE MODEL OF SEPSIS , 2007, Shock.

[36]  M. Hoth,et al.  P2X7 receptor stimulation upregulates Egr‐1 biosynthesis involving a cytosolic Ca2+ rise, transactivation of the EGF receptor and phosphorylation of ERK and Elk‐1 , 2007, Journal of cellular physiology.

[37]  G. Burnstock,et al.  Purine and pyrimidine receptors , 2007, Cellular and Molecular Life Sciences.

[38]  Z. Ou,et al.  Overexpression of Ecto-5'-Nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix , 2007, Cancer biology & therapy.

[39]  Linda Yip,et al.  ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors , 2006, Science.

[40]  W. Gan,et al.  The P2Y12 receptor regulates microglial activation by extracellular nucleotides , 2006, Nature Neuroscience.

[41]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[42]  A. Richmond,et al.  Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. , 2006, Cancer research.

[43]  J. Sévigny,et al.  The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance , 2006, Purinergic Signalling.

[44]  G. Kong,et al.  The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor–positive and estrogen receptor–negative human breast cancers , 2006, Molecular Cancer Therapeutics.

[45]  Seiko F. Okada,et al.  Nucleotide Release Provides a Mechanism for Airway Surface Liquid Homeostasis* , 2004, Journal of Biological Chemistry.

[46]  P. Insel,et al.  A putative osmoreceptor system that controls neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2 adenosine and P2 receptors , 2004, Journal of leukocyte biology.

[47]  P. Fishman,et al.  An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB , 2004, Oncogene.

[48]  G. Borisy,et al.  Cell Migration: Integrating Signals from Front to Back , 2003, Science.

[49]  P. Fishman,et al.  Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. , 2003, Anticancer research.

[50]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[51]  B. Fredholm,et al.  Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. , 2001, Biochemical pharmacology.

[52]  R. Hipskind,et al.  Extracellular ATP activates multiple signalling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells. , 2000, Carcinogenesis.

[53]  R. K. Shepherd,et al.  Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. , 1997, The Journal of clinical investigation.

[54]  J. Blay,et al.  The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. , 1997, Cancer research.

[55]  G. Schatten,et al.  Adhesion of cells to surfaces coated with polylysine. Applications to electron microscopy , 1975, The Journal of cell biology.

[56]  B. Paradiso,et al.  The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. , 2013, European journal of cancer.

[57]  J. Sévigny,et al.  Impact of ectoenzymes on p2 and p1 receptor signaling. , 2011, Advances in pharmacology.

[58]  P. Fishman,et al.  The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. , 2008, International journal of oncology.

[59]  F. Karami-Tehrani,et al.  Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. , 2007, Oncology research.

[60]  P. Fishman,et al.  An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. , 2004, Oncogene.